Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

AcroMetrix launches first liquid MRSA positive control

AcroMetrix : 26 March, 2008  (New Product)
AcroMetrix has launched the OptiQual MRSA Positive Control which is the first standardised external quality control for Methicillin Resistant Staphylococcus aureas (MRSA) molecular testing.
The OptiQual MRSA Positive Control may be used to independently monitor all phases of MRSA DNA testing to ensure consistent and accurate results.

A study published October 2007 in the Journal of the American Medical Association estimated that MRSA infections resulted in the death of 18,650 out of 94,360 infected patients in the USA in 2005 - death rate higher than that of HIV/AIDS in the same year. Since then, many efforts have been highlighted to urge state and federal lawmakers to enact a bill requiring all incoming hospital patients be screened for MRSA upon being admitted.

The costs involved when MRSA spreads through a hospital are staggering. The VA Medical Center of Pittsburgh estimated in September 2007 that nearly $35,000 is spent per patient in treatment for MRSA. In addition, the website for the Center for Medicare and Medicaid services states that CMS is analysing the need to adjust reimbursements for hospital-acquired infections such as MRSA.

'With the urgency currently associated with the MRSA screening, it is critical that hospitals are able to implement screening tests with the appropriate level of quality control,' said Michael J Eck, president and chief executive officer of AcroMetrix. 'Many critical and costly treatment decisions will be based on the results of these tests so it is important for patients that the tests are properly monitored during all phases of the testing procedure.'

Each lab can help to maintain CLIA compliance for qualitative PCR tests such as those used to detect MRSA DNA by using the OptiQual MRSA Positive Control daily. These controls contain inactivated whole MRSA bacteria, providing a safer method of monitoring the entire PCR process, from extraction through amplification and detection. Convenient and ready to use, the OptiQual MRSA Positive Control is stored at refrigerated temperatures.

The product is for research use only. Not for use in diagnostic procedures.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo